invest tafasitamab support mid/long-term growth rais price
reiter market outperform rate incyt corpor
increas price target previous base discount
earn per share revenu multipl analysi yesterday
morphosi mor mo pt butler sign global collabor licens
agreement tafasitamab pay cash upon close
deal up-front payment equiti invest mor
view collabor net posit compani gain
signific mid/long-term revenu driver morphosi gain access
establish hematology/oncolog network expertis rux pois
gener sale pemigatinib obtain prioriti review
may pdufa data novarti nv nc begin world-wid file
sr-agvhd phase trial run compani dermatolog
franchis peak revenu tafasitamab expect reach
post-agr cash posit pro forma continu recommend
share
co-commerci exclus commerci
right ex-u term agreement morphosi
 co-commerci tafasitamab morphosi fc-engin
antibodi develop treat cell malign profit loss
share ex-u exclus commerci right pay
morphosi tier royalti mid-teen mid-twenti net sale addit
up-front payment equiti invest morphosi
elig receiv mileston payment respect futur
develop cost pay cost global
specif trial ex-u specif trial
ad tafasitamab model morphosi recent submit bla
tafasitamab combin lenalidomid r/r dlbcl fda
potenti approv compani plan submit
ema indic lead potenti
approv base strong clinic result gener date
collabor jason butler cover morphosi ascrib
probabl success dlbcl cll model
translat addit revenu termin
year model figur view tafasitamab import mid/long-
term growth driver potenti account revenu
figur achiev peak risk-adjust revenu
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
synergi hematolog network discuss confer call
footprint hematolog oncolog space eu major contribut
factor morphosi decis secur partnership gener
consider success build myelofibrosi polycythemia vera market
salesperson new drug promot believ allow
maxim likelihood rapid effect launch respect eu
spent last four year build team alreadi capabl cover
compani estim potenti eu market tafasitamab next month
plan increas eu footprint consequ increas sg estim
global launch proce
report thousand dlbclclltotal address patient popul annual wac address market opportun address patient popul annual wac address market opportun market opportun us dlbcl cll market opportunitiesyear market penetr achiev market penetr success adjust revenu market penetr achiev market penetr success revenu revenu us revenu risk-adjust revenu incyt corpor
figur revenu growth expect product indic
potenti approv pemigatinib second-lin mutant cholangiocarcinoma
potenti report updat phase ii data pemigatinib bladder cancer
rux itacitinib franchis
potenti report phase result trial
potenti initi phase trial rux plu combin mf
potenti report result itacitinib phase studi sn-cgvhd
potenti report initi true-ad clinic trial result
potenti nda submiss rux cream ad
potenti report initi true-v clinic trial result
potenti submiss tafasitamab dlbcl
product revenu million revenu product revenu million revenu increas jakavi royalti mf royalti dilut ruxolitinib revenu split mf pv known includ potenti off-label use rux incyt corpor
potenti approv tafasitamab dlbcl
potenti approv capmatinib novarti nsclc c-met-mutation-posit
potenti report data parsaclisib fl mcl mzl
potenti report data metastat squamou carcinoma anal canal
potenti report initi data solid tumor
valu biotechnolog compani base blend discount earn per share revenu
multipl analysi first evalu univers profit biotechnolog compani deriv
revenu multipl rang ep multipl rang base compani trade bear
bull market end ascertain rang revenu multipl
earn per share multipl
appli price-to-earnings multipl probability-adjust earn per share approxim
discount period obtain fair valu per share appli
revenu multipl probability-adjust revenu discount
period obtain per share fair valu averag result two method
ad anticip cash per share million share deriv price
target round
figur blend discount earn per share revenu multipl analysi
revenu estim combin increas sale exist commerci
product ruxolitinib mf pv sr-agvhd ponatinib cml baricitinib ra
potenti sale product believ high likelihood approv pemigatinib
cholangiocarcinoma tafasitamab dlbcl cll ruxolitinib sr-cgvhd
base scenario includ potenti revenu rux cream sale mild
moder ad vitiligo pemigatinib sale bladder cancer itacitinib sn-cgvhd
bull scenario adjust probabl success program base
confid data seen far includ risk-adjust revenu key pipelin product
valuat figur result fair valu
bear scenario remov risk-adjust revenu pemigatinib lower probabl
success tafasitamab assum lower-than-expect long-term jakafi sale base
scenario fair valu
bullbasebearrux cream ad cream ad cream vitiligo cream vitiligo sr-cgvhd sr-agvhd sr-cgvhd cholangio uretheli cancer cholangio uretheli cancer sn-agvhd sn-cgvhd sn-agvhd sn-cgvhd dlbcl dlbcl cll cll revenu mm dilut non-gaap ep success incyt corpor
figur chart incyt close price previou month price project
compani could achiev month bull base bear case scenario
revenu increas includ tafasitamab dlbcl cll
expens increas match increas commerci develop cost associ
incyt corpor incom statementfigur thousand except per share revenu jakafi itacitinib gvhd iclusig eu rux cream ad -- -- -- -- tafasitamab dlbcl cll pemigatinib cholangio uc -- total product revenu product royalti contract revenue- mileston total non- total non- expens good research sell gener chang fair valu acquisition-rel conting consideration- total non- total non- incom loss unreal gain loss long term interest incom expens non- net loss incom incom incom tax expens non- net loss incom common non- net loss incom earn per share basic dilut basic dilut averag share outstand dilut incyt corpor figur incom statement annual
incyt corpor incom statementfigur thousand except per share revenu jakafi itacitinib gvhd iclusig eu rux cream ad tafasitamab dlbcl cll pemigatinib cholangio uc total product revenu product royalti contract revenue- mileston total non- total non- expens good research sell gener chang fair valu acquisition-rel conting consideration- total non- total non- incom loss unreal gain loss long term interest incom expens non- net loss incom incom incom tax expens non- net loss incom common non- net loss incom earn per share basic dilut basic dilut averag share outstand dilut incyt corpor incyt corpor
wilmington delaware-bas incyt corpor drug discoveri develop compani grow pipelin novel small-molecul
drug treat variou inflammatori disord cancer
risk invest thesi valuat includ clinic develop competit regulatori sector
clinic develop risk drug develop riski capital-intens endeavor major drug enter clinic develop
fail reach market
competit risk drug market develop condit program address lack
differenti clinic data drug and/or approv competit drug may advers impact sale potenti product
regulatori risk like drug develop compani reliant upon fda pace evalu new drug agenc
willing approv new drug
sector risk valuat biotechnolog stock subject investor assess prospect underli compani investor
toler risk confid prospect biotechnolog stock group therefor stock price may fall even
compani meet exce investor expect
